FDA de­lays PDU­FA date for Lib­tayo lung can­cer com­bo; Swedish biotech hit flunks PhI­II for chemo-en­hanc­ing drug

Dur­ing its earn­ings call yes­ter­day, Re­gen­eron said that the FDA has de­layed its de­ci­sion on Lib­tayo in com­bi­na­tion with chemother­a­py in ad­vanced non-small cell lung …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER